Samraat S. Raha insider trades: Myriad Genetics (MYGN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Samraat reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | MYGN | ↑ Buy | 40,000 | $5.00 | $200K | Direct | Mar 9, 2026 (0d) |
| Mar 31, 2021 | A | ↓ Sell | 1,000 | $127.50 | $128K | Direct | Apr 1, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MYGN insiders
Open-market trades in the last 12 months
About Samraat S. Raha's insider trades
Samraat S. Raha is President and CEO at Myriad Genetics (MYGN). Since Mar 31, 2021, Samraat has reported 1 open-market purchase worth $200K and 1 sale worth $128K on SEC Form 4. In the last 12 months: 1 buy ($200K).
Their filings also include shares withheld for taxes (28 filings), grants and awards (15 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MYGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.